Well, all I can say to that is...how does he know
Evidence showed, as mentioned, wide therapy counteracting potential (NO-release, NO-synthase (NOS)-inhibition (L-NAME), NOS-over-activity (L-arginine), NO-system immobilization (L-NAME+L-arginine)
By Paula from Jamaica - 2018.06.05 13:10
BPC-157 has been discussed by the FDA in the context of bulk drug substances that may present significant safety risks, and TB-500 is generally promoted in research-peptide settings rather than as an FDA-approved therapeutic product
Potential for Chronic Pain Management: By promoting tissue repair and reducing inflammation, BPC-157 might help individuals suffering from chronic pain, particularly related to musculoskeletal injuries or conditions like arthritis
Choline can be made in the liver